Recursion announced Najat Khan, PhD, currently chief R&D and commercial officer and a board member, will succeed co-founder and CEO Chris Gibson, PhD as CEO and president. Khan will also continue in ...
Gibson highlighted, "Recursion has a tremendous amount of potential catalysts coming in the next 18 months," referencing the pipeline, partnerships, and platform advancements. He reported, "a pro ...
Achieved $30 million milestone from Roche and Genentech for delivering a whole-genome map of microglial immune cells—the second neuro map ...
Recursion's approach is intriguing, as evidenced by the fact that several of the world's largest pharmaceutical companies ...
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
We recently published 10 Stocks Stealing Today’s Spotlight; 5 on All-Time Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the best performers on Wednesday. Recursion Pharmaceuticals ...
In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...
Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about ...
Abstract: Multi-modal image synthesis is crucial for obtaining complete modalities due to the imaging restrictions in reality. Current methods, primarily CNN-based models, find it challenging to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback